Results 51 to 60 of about 659,276 (230)

Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration. [PDF]

, 2015
The gut incretin glucagon-like peptide-1 (GLP-1) and the intestinotropic hormone GLP-2 are released from enteroendocrine L cells in response to ingested nutrients.
Abe, Yosuke, Akiba, Yasutada, Fujiwara, Kaori, Fukunishi, Shinya, Higuchi, Kazuhide, Iguchi, Munetaka, Inoue, Takuya, Ishida, Kumi, Kakimoto, Kazuki, Kaunitz, Jonathan D, Masuda, Daisuke, Narabayashi, Ken, Nouda, Sadaharu, Okada, Toshihiko, Sakanaka, Taisuke, Takeuchi, Toshihisa, Umegaki, Eiji, Yorifuji, Naoki   +17 more
core   +1 more source

Uncoupling Protein-2 Mediates DPP-4 Inhibitor-Induced Restoration of Endothelial Function in Hypertension Through Reducing Oxidative Stress [PDF]

, 2014
published_or_final_versio
Gao, Y, Huang, Y, Lau, CW, Liu, J, Liu, L, Ng, CF, Tian, XY, Wong, WT, Xu, A, Xu, G, Yao, X   +10 more
core   +1 more source

Rational design of a (S)-selective-transaminase for asymmetric synthesis of (1S)-1-(1,1′-biphenyl-2-yl)ethanamine [PDF]

, 2016
Amine transaminases offer an environmentally sustainable synthesis route for the production of pure chiral amines. However, their catalytic efficiency toward bulky ketone substrates is greatly limited by steric hindrance and therefore presents a great ...
Allen, Christopher C.R., Brown, Rodney T., Carvalho, Alexandra T.P., Caswell, Jill M., Dheeman, Dharmendra S., Dourado, Daniel F.A.R., Huang, Meilan, Kulakov, Leonid, Miskelly, Iain, Moody, Thomas S., Pohle, Stefan, Quinn, Derek J., Skvortsov, Timofey   +12 more
core   +3 more sources

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study [PDF]

Endocrinology and Metabolism, 2016
BackgroundThe use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been ...
Jaehyun Bae, Min Jung Lee, Eun Yeong Choe, Chang Hee Jung, Hye Jin Wang, Myoung Soo Kim, Yu Seun Kim, Joong-Yeol Park, Eun Seok Kang   +8 more
doaj   +1 more source

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

BI-LAYER TABLETS OF SITAGLIPTIN PHOSPHATE & METFORMIN HYDROCHLORIDE - PREPARATION AND EVALUATION

Prospects in Pharmaceutical Sciences
Bi-layer tablets with sitagliptin phosphate as a Immediate Release (IR) layer and metformin HCl as a Sustained Release (SR) layer were developed for hypoglycemic control. The IR formulations were formulated using Aegle marmelos gum (natural antidiabetic agent and disintegrant) by direct compression method and was found to have good pre- and post ...
Sailaja Gunnam, T Sindhura, Rajeswari Aleti, Monika Nijhawan   +3 more
openalex   +3 more sources

Simultaneous HPLC determination of remdesivir and dexamethasone in the presence of metformin, sitagliptin, and glimepiride in a synthetic mixture and spiked human plasma [PDF]

Pharmacia
The COVID-19 pandemic has raised many questions regarding the control and therapy of type 2 diabetes and the higher risk of severe disease progression. One of the therapeutic regimens used in moderate and severe cases of COVID-19, endorsed by the World ...
Stanislav Bozhanov, Miglena Smerikarova, Vania Maslarska   +2 more
doaj   +3 more sources

A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice [PDF]

, 2005
ObjectivesThe aim of this study was to investigate the antiatherogenic effects of the dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin (DFS).BackgroundThe new class of anti–type 2 diabetes drugs, dipeptidyl peptidase-4 inhibitors, improves ...
Matsubara, Junichi, Sugiyama, Seigo, Sugamura, Koichi, Nakamura, Taishi, Fujiwara, Yukio, Akiyama, Eiichi, Kurokawa, Hirofumi, Nozaki, Toshimitsu, Ohba, Keisuke, Konishi, Masaaki, Maeda, Hirofumi, Izumiya, Yasuhiro, Kaikita, Koichi, Sumida, Hitoshi, Jinnouchi, Hideaki, Matsui, Kunihiko, Kim-Mitsuyama, Shokei, Takeya, Motohiro, Ogawa, Hisao   +18 more
core   +1 more source

A survey of Top 200 Drugs—Inconsistent Practice of Drug Strength Expression for Drugs Containing Salt Forms [PDF]

, 2012
Many ionizable drugs are developed and marketed as salt forms. However, there are no clear US regulatory guidelines on drug strength labeling for salts. The strengths of some drugs are expressed as salts and some as free acids/bases.
Prohotsky, Daniel, Zhao, Fang
core   +2 more sources

Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®)

Dermatology Online Journal, 2012
Photosensitivity to sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is reported. No previous reports of photosensitivity to any DPP-4 inhibitors are known. Physical examination of the patient revealed edematous plaques confined to sun-exposed areas of the skin.
Stricklin, Sherea M, Stoecker, William V, Rader, Ryan K, Hood, Antoinette F, Litt, Jerome Z, Schuman, Thomas P   +5 more
openaire   +4 more sources